In conclusion, aberrant overexpression of LAT1 in bile duct adenocarcinoma predicts poor prognosis, suggesting that LAT1 may be a potential target of anticancer therapy. This evidence concerns the gene SLC7A5 and bile duct adenocarcinoma.